- Report
- June 2025
- 190 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- January 2025
- 180 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- March 2025
- 185 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- March 2025
- 182 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- February 2025
- 180 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- February 2025
- 180 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- January 2025
- 180 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- August 2024
- 185 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- July 2024
- 185 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1337EUR$1,500USD£1,159GBP
- Drug Pipelines
- June 2025
- 150 Pages
Global
From €3342EUR$3,750USD£2,898GBP
- Clinical Trials
- April 2025
- 550 Pages
Global
From €4455EUR$5,000USD£3,864GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2673EUR$3,000USD£2,319GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2228EUR$2,500USD£1,932GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1782EUR$2,000USD£1,546GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2673EUR$3,000USD£2,319GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €4455EUR$5,000USD£3,864GBP
- Drug Pipelines
- April 2025
- 200 Pages
Global
From €2228EUR$2,500USD£1,932GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1337EUR$1,500USD£1,159GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1337EUR$1,500USD£1,159GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more